Bremelanotide

Bremelanotide is a prescription injection sold in the United States under the brand name Vyleesi. It is approved to treat acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women: low sexual desire that is new for that person, happens in most situations, and causes real distress. It is used on demand, not daily.

That short definition rules out most of what people assume. It is not a pill. It is not approved for men. It is not approved after menopause. And it does not work on blood flow the way erectile dysfunction medicines do. What follows is the plain-English version of the label, the trial evidence, the safety fine print and the money.

What this medicine is, and who the label is written for

The product is a single-use autoinjector. A patient gives the dose under the skin of the abdomen or thigh at home, ahead of anticipated sexual activity. The approved product is a prescription drug, not a supplement, and not something you can legally buy without a clinician. The US regulator cleared it for this narrow use, as described in an official announcement about the approval decision, FDA approval of a treatment for HSDD.

The two words in the indication carry weight. Acquired means the low desire developed in someone who did not have that problem before. Generalized means it happens regardless of the partner, the setting or the type of stimulation. Both have to be true.

The label is also explicit about what HSDD is not. It excludes low desire that comes from another medical or mental health condition, from problems in the relationship, or from the effect of a medication or substance. In practice that makes HSDD a diagnosis of exclusion. A careful intake should ask about depression and anxiety, thyroid and hormone issues, pain with sex, sleep, alcohol, and the long list of common drugs that blunt desire, including some antidepressants and blood pressure medicines. If one of those is driving the problem, treating that cause is the more useful move.

Two groups are outside the approved use. Safety and effectiveness have not been established in men, and the indication is limited to premenopausal women, so use after menopause sits outside the label as well. Patient-facing summaries from major hospitals cover the same ground, for example this reference page on bremelanotide injection basics.

How it works in the brain, and how long one dose lasts

This drug is a melanocortin receptor agonist. In plain terms, it switches on receptors in brain pathways that help regulate desire and reward. The subtype thought to matter most at treatment doses is MC4R. That is a very different target from the erectile dysfunction drugs, which relax blood vessels so more blood reaches genital tissue. A published review of the mechanism is available through the National Library of Medicine, on the neurobiology of melanocortin agonists.

Timing is the question people ask most. The labeling has patients inject at least 45 minutes before anticipated sexual activity, and it caps use at one dose in any 24 hours and no more than eight doses in a month. Blood levels peak within about an hour, and the drug clears quickly, with a half-life measured in a few hours rather than days. So the effect is a window, not a steady state, and there is no build-up between doses.

Two practical notes follow from that. First, some people need a few attempts to work out their own best timing inside the label limits. Second, the labeling addresses stopping if there is no improvement after a reasonable trial, so ask at the first visit how long you will try it and what counts as a result worth continuing.

On the results themselves, keep expectations grounded. In the two pivotal 24-week studies, average desire scores improved more than with placebo and distress scores fell, but the improvements were modest and the trials did not show a meaningful increase in the number of satisfying sexual events. The primary trial write-up is published in a peer-reviewed obstetrics journal, in this report on randomized trials in premenopausal women.

Side effects people actually report

Nausea dominates the side effect profile. In the pivotal trials it was reported by roughly four in ten participants, far more often than with placebo. It tends to show up within the first hours after a dose, is often worst with the first dose, and eases for many people with later doses. Some participants used an anti-nausea medicine, and nausea was among the most common reasons people stopped treatment altogether.

Other reactions reported often enough to expect them include:

• flushing, or sudden warmth in the face and chest
• injection site reactions such as redness, itching or a small bruise
• headache
• vomiting
• cough, nasal congestion or a tickle in the throat
• tiredness and dizziness

Focal hyperpigmentation, meaning darkened patches of skin, was reported by about 1% of patients using up to eight doses per month, including on the face, the gums and the breasts. Risk appears higher in people with darker skin and with more frequent dosing, and the change may not fully fade after stopping. That is a side effect worth deciding about in advance, not discovering later.

If you experience a side effect that concerns you, tell the prescriber. Patients and caregivers can also report problems directly to the regulator through the FDA adverse event reporting program.

Warnings worth reading twice

The most important warning is cardiovascular. Each dose causes a temporary rise in blood pressure and a fall in heart rate, and this usually settles within about 12 hours. Because of that, the labeling says to consider cardiovascular risk before starting and periodically during treatment, and to make sure blood pressure is well controlled first. It is not recommended for people at high risk of cardiovascular disease, and it should not be used by people with uncontrolled high blood pressure or known cardiovascular disease.

That makes a blood pressure reading part of a legitimate workup, not an optional extra. If you already take home readings, averaging them across several days gives a clearer picture than a single cuff measurement.

The skin pigmentation warning above is the second item on the label’s precautions list, and it is the reason the monthly dose cap exists. Daily use was associated with more pigmentation, so more is not better here.

Pregnancy and breastfeeding are covered in the labeling too. If you are pregnant, might become pregnant, or are nursing, raise it before the first dose and follow the label guidance your clinician gives you. There is no boxed warning on this product, which is the regulator’s most serious label alert, but the absence of one does not make the cardiovascular and pigmentation cautions optional.

Interactions: how one injection can change your other pills

The interaction story is unusual and easy to miss. Bremelanotide slows how quickly the stomach empties. That means an oral medicine taken around the same time can be absorbed more slowly, or less completely, than usual.

Two consequences matter most:

• Oral naltrexone. The labeling advises against combining them, because reduced naltrexone exposure could mean that treatment for alcohol or opioid use disorder stops doing its job.
• Oral drugs with a narrow safety window. Where a small change in blood level matters, such as some anti-seizure, thyroid, heart rhythm or anticoagulant medicines, the timing question should be settled by the prescriber, not guessed at.

Give any prescriber a full list: prescriptions, over-the-counter products, birth control, supplements and peptides. Note that the approved injection does not carry the alcohol-related boxed warning that the daily oral HSDD pill does, but alcohol can still stack onto nausea, flushing and dizziness.

Injection, nasal spray, PT-141 and compounded copies

You will see this molecule called PT-141. That was its development code name, and it is why the peptide has a second life in the gray market. Earlier research explored other routes, including an intranasal formulation that was not brought to approval; the background is catalogued in a federal research database entry on this peptide’s development history. The approved product in the United States is the subcutaneous autoinjector. There is no FDA-approved nasal spray, oral tablet or generic version, which you can confirm yourself in the regulator’s approved products database, Drugs@FDA product search.

Compounded PT-141 is a different category, and this is the part that gets glossed over in marketing. Compounded preparations are not FDA-approved and are not reviewed for safety, effectiveness or quality before they are sold, even when the active ingredient also exists in an approved drug. Compounders come in two flavors: 503A pharmacies, which make preparations for individual patients on a prescription, and 503B outsourcing facilities, which register with the FDA and follow stricter manufacturing rules. The agency explains the split in its overview of human drug compounding rules, and it has raised safety questions about certain bulk peptide ingredients used for compounding.

Vials advertised as “research use only” are not a legal or sensible shortcut, and sellers offering injectable peptides with no prescriber involved are a warning sign in themselves. If you want to sanity check a pharmacy or telehealth site, third-party certification records such as those published by LegitScript for healthcare merchants are a starting point. For related compounds and how each is regulated, the Medication Index lists the guides side by side.

What a month costs when you pay yourself

Tracked self-pay pricing for this compound runs from to a month. All figures on this site are US dollars per month, and cash pay is tracked separately from the insurance route, where the number reflects only the plan or membership fee and excludes copays and deductibles that differ by plan and state.

Because this drug is used on demand, a monthly figure hides a lot. Ask what the number actually buys:

• Brand or compounded. These are different products with different oversight, and the price gap between them is usually the largest single factor.
• How many autoinjectors or doses. Two programs quoting similar monthly figures can supply very different amounts.
• Pharmacy and shipping. Which pharmacy fills the prescription, and whether shipping is bundled.
• Program fees. Consult fees, membership fees and refill fees are sometimes separate line items.
• Included care. Whether follow-up messaging, dose questions and blood pressure review are part of the price.
• Intro versus renewal. A first-month figure that jumps at renewal is common across telehealth pricing.

Advertised self-pay prices change often, so treat any figure as a snapshot and re-check before you commit. Since usage is episodic, annualizing helps you compare an on-demand medicine against a daily one.

On the insurance side, coverage for HSDD treatments has never been consistent, and prior authorization requirements and denials are common for drugs in this category. Never assume coverage: call the number on your card, ask whether the specific product is on formulary, and ask what documentation a prescriber must submit. For background on how benefit design shapes access to women’s health drugs, policy research from KFF on health coverage and costs is useful context. If you want to see how monthly self-pay figures are laid out for comparison, the Sample Savings Report shows the format, and the Free Health Calculators page covers the cost math in more detail.

How telehealth programs differ on this prescription

Programs that prescribe this treatment online are not interchangeable. The differences that matter are clinical, not cosmetic:

• Intake depth. Because HSDD is defined by exclusion, a short questionnaire cannot do the job well. Look for programs that ask about mood, medications, menopause status, pain and relationship context.
• Cardiovascular screening. Given the blood pressure warning, ask whether a recent reading and cardiac history are required before a first prescription.
• Prescriber disclosure. Whether you can see who is prescribing, their license type and their state.
• Product supplied. Brand or compounded, and if compounded, which pharmacy.
• Follow-up. Whether there is a scheduled check-in, and how side effects are handled between visits.
• Cancellation and refills. How easy it is to pause, and whether refills auto-ship.
• State rules. Telemedicine prescribing and compounding rules vary by state, so availability differs by address.

You can browse programs by condition and molecule in the Telehealth Provider Directory, see how the six scoring dimensions are weighted on the Scoring Methodology page, and read broader analysis in the Telehealth Analysis Archive.

Questions for your clinician, and when to get help fast

Bring a written list to the visit. Useful questions include: is my low desire likely to be HSDD, or is something else driving it; what is my blood pressure and is it controlled well enough; do any of my current medicines interact; what is the plan if nausea is bad after the first dose; how long will we try this before deciding it is not working; am I getting the approved product or a compounded one; and what are the non-drug options, including sex therapy and treating a contributing condition.

Some symptoms are not wait-and-see. Get urgent medical help if you have any of the following after a dose:

1. chest pain, pressure, or a very fast or irregular heartbeat
2. a severe or unusual headache, especially with a high blood pressure reading
3. fainting, near-fainting or new confusion
4. signs of an allergic reaction such as swelling of the face, lips or tongue, hives, or trouble breathing
5. vomiting that will not stop, or signs of dehydration

Also call your prescriber, without an emergency, if you notice darkening patches of skin, blood pressure readings that stay high, or a new or worsening low mood. None of these should be managed by guessing at your own dose.

Authoritative sources

• The full approved prescribing information for this product: FDA-approved product labeling
• Current labeling records maintained by the National Library of Medicine: DailyMed label database
• Patient-facing summary from a major US medical center: Mayo Clinic drug information

Educational content, not medical advice. Always consult a qualified clinician before starting, stopping or switching treatment.